Wahn Friederike, Daniel Volker, Kronenberg Florian, Opelz Gerhard, Michalk Dietrich V, Querfeld Uwe
University Children's Hospital, Charité, Berlin, Germany.
Institute for Transplant Immunology, University of Heidelberg, Germany.
J Am Soc Nephrol. 2001 May;12(5):1052-1058. doi: 10.1681/ASN.V1251052.
The long-term success of renal transplantation is limited because of chronic rejection (CR), which shows histologic parallels to atherosclerosis. Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerosis, but its role in CR has not been investigated. Plasma levels of Lp(a) are determined mainly by the inherited isoform (phenotype) of apolipoprotein(a) [apo(a)] and show an inverse correlation with the molecular weight of apo(a). Apo(a) isoforms were identified in frozen sera of 327 patients who received a renal transplant during 1982 to 1992. Long-term graft survival in recipients with high molecular weight (HMW) or low molecular weight (LMW) apo(a) phenotypes were compared retrospectively. Mean (95% confidence interval) transplant survival was 12.8 yr (range, 11.9 to 13.6 yr) in patients with HMW and 11.9 yr (range, 10.8 to 13.1 yr) in patients with LMW apo(a) phenotypes (P = 0.2065). In patients who were 35 yr or younger at the time of transplantation, mean transplant survival was more than 3 yr longer in recipients with HMW apo(a) phenotypes compared with those with LMW apo(a) phenotypes (13.2 yr [range, 12.1 to 14.4 yr] versus 9.9 yr (range, 8.5 to 11.5 yr); P = 0.0156). In a Cox's proportional hazards regression model, the presence of LMW phenotypes-but not gender, immunosuppression, or HLA mismatches-in young patients was associated with a statistically significant risk of CR (P = 0.0434). These retrospective data indicate that young renal transplant recipients with LMW apo(a) phenotypes have a significantly shorter long-term graft survival, regardless of the number of HLA mismatches, gender, or immunosuppressive treatment.
由于慢性排斥反应(CR),肾移植的长期成功率受到限制,慢性排斥反应在组织学上与动脉粥样硬化相似。脂蛋白(a)[Lp(a)]是动脉粥样硬化的独立危险因素,但其在慢性排斥反应中的作用尚未得到研究。血浆Lp(a)水平主要由载脂蛋白(a)[apo(a)]的遗传异构体(表型)决定,并与apo(a)的分子量呈负相关。在1982年至1992年期间接受肾移植的327例患者的冷冻血清中鉴定出apo(a)异构体。对具有高分子量(HMW)或低分子量(LMW)apo(a)表型的受者的长期移植物存活情况进行了回顾性比较。HMW患者的平均(95%置信区间)移植存活时间为12.8年(范围为11.9至13.6年),LMW apo(a)表型患者为11.9年(范围为10.8至13.1年)(P = 0.2065)。在移植时年龄为35岁或更小的患者中,HMW apo(a)表型的受者的平均移植存活时间比LMW apo(a)表型的受者长3年以上(13.2年[范围为12.1至14.4年]对9.9年(范围为8.5至11.5年);P = 0.0156)。在Cox比例风险回归模型中,年轻患者中LMW表型的存在——而非性别、免疫抑制或HLA错配——与CR的统计学显著风险相关(P = 0.0434)。这些回顾性数据表明,无论HLA错配数量、性别或免疫抑制治疗如何,具有LMW apo(a)表型的年轻肾移植受者的长期移植物存活时间明显更短。